The Neurobiology of Hope: Integrating Ketamine into the Oncology Paradigm | West Eastern Health

A Comprehensive White Paper on the Intersection of Mental Health, Pain Management, and Cancer Care West Eastern Health | Date: October 2025

1. Introduction: The Silent Epidemic in Oncology

The trajectory of modern oncology has been defined by a relentless pursuit of survival. Through the advent of targeted immunotherapies, precision genomics, and advanced surgical techniques, we have successfully transformed many terminal diagnoses into manageable chronic conditions. Yet, in this singular focus on extending the quantity of life, medicine has often overlooked the profound degradation in the quality of that survival. A silent epidemic pervades the oncology ward, one that is not detected by PET scans or tumor markers but is measured in the quiet despair of the patient. This epidemic is the twin burden of refractory mental health distress and unmanageable pain, a convergence of suffering that traditional care models are failing to address adequately.

The prevalence of psychiatric comorbidity in cancer patients is staggering. Estimates suggest that between 25% and 30% of all oncology patients meet the clinical criteria for depression, anxiety, or a distinct syndrome known as "demoralization". This is not merely a reaction to bad news; it is a complex physiological and psychological state driven by the systemic inflammation of the malignancy itself, the neurotoxic effects of chemotherapy, and the existential confrontation with mortality.

For decades, the standard of care for these "psychological tumors" has been the prescription of Selective Serotonin Reuptake Inhibitors (SSRIs) and classic talk therapy. While valuable tools, they possess inherent limitations in the oncology setting — most notably, a latency of onset that requires weeks to manifest efficacy. For a patient with advanced disease, waiting six weeks for relief is a luxury they cannot afford. Similarly, in the domain of pain management, the reliance on escalating doses of opioids has led to a secondary crisis of sedation, tolerance, and opioid-induced hyperalgesia (OIH), leaving patients in a fog of cognitive impairment without true relief.

This white paper posits that the field of integrative oncology stands at the precipice of a paradigm shift. Emerging research points to Ketamine — a dissociative anesthetic with a fifty-year safety record — as a potent, rapid-acting intervention that bridges the gap between biological psychiatry and palliative care. By targeting the glutamatergic system and modulating neuro-inflammation, ketamine offers a unique mechanism of action that addresses both the "chemical" and "existential" dimensions of cancer distress.

West Eastern Health recognizes this urgent clinical need. By integrating ketamine therapy into a holistic framework that includes nutritional support, mindfulness, and specialized psychotherapy, we aim to provide a comprehensive solution for the whole patient — mind, body, and spirit. This report provides an exhaustive analysis of the scientific evidence, clinical applications, and safety considerations of ketamine in the cancer population, offering a roadmap for its use as a transformative tool in modern oncology.

2. The Psych-Oncology Crisis: Understanding the Unmet Need

To appreciate the potential of ketamine, one must first confront the inadequacy of our current tools. The mental health burden in cancer is distinct from that of the general population, characterized by unique biological drivers and profound existential dimensions that resist standard pharmacological approaches.

2.1 The Prevalence and Impact of Distress

The intersection of cancer and mental health is a crowded one. Studies indicate that up to 73% of cancer patients with major depressive disorder do not receive effective treatment. This treatment gap is not merely a quality-of-life issue; it is a survival issue. Depression in cancer patients is an independent prognostic factor for mortality. It is associated with poorer adherence to complex chemotherapy regimens, prolonged hospitalizations, and a dampened immune response that may theoretically facilitate tumor progression.

Furthermore, the distress is often misdiagnosed. A significant proportion of cancer patients suffer from Demoralization Syndrome, a condition distinct from depression characterized by a sense of helplessness, hopelessness, and a loss of meaning, yet often with preserved capacity for pleasure. Unlike depression, which is a mood disorder, demoralization is a disorder of "meaning," rooted in the existential threat of the illness. Standard antidepressants, which target mood-regulating neurotransmitters like serotonin, are notoriously ineffective at treating this existential collapse.

2.2 The Limitations of the Serotonin Model (SSRIs)

The "Serotonin Hypothesis" — the idea that depression is caused simply by low serotonin — is increasingly viewed as an oversimplification, particularly in the medically ill. In the context of cancer, the use of SSRIs (e.g., escitalopram, fluoxetine) presents specific challenges:

Latency of Efficacy: The primary limitation is time. SSRIs typically require 4 to 6 weeks to achieve therapeutic blood levels and induce the downstream neuroplastic changes required for symptom relief. In the palliative care setting, where timelines are compressed, this delay is clinically unacceptable. Patients in acute distress or those nearing the end of life require immediate relief.
Adverse Effect Burden: The side effect profile of SSRIs — nausea, gastrointestinal motility issues, insomnia, and sexual dysfunction — overlaps heavily with the toxicity of chemotherapy. Adding an agent that causes nausea to a patient already struggling with chemotherapy-induced emesis often leads to non-adherence.
Lack of Efficacy in "Sickness Behavior": Cancer-related depression is often driven by inflammatory cytokines rather than simple serotonin depletion. SSRIs generally do not address this inflammatory etiology, which may explain the high rates of treatment resistance in this population.

2.3 The Opioid Dilemma in Pain Management

Parallel to the mental health crisis is the challenge of pain control. The World Health Organization's analgesic ladder has long relied on opioids as the cornerstone of cancer pain management. While effective for acute nociceptive pain, opioids are less effective for neuropathic pain — the burning, shooting pain caused by tumor infiltration of nerves or chemotherapy-induced peripheral neuropathy (CIPN).

The consequences of long-term high-dose opioid therapy are severe:

Opioid-Induced Hyperalgesia (OIH): Paradoxically, chronic opioid exposure can sensitize the nervous system, making the patient more sensitive to pain. This leads to a vicious cycle of dose escalation and diminishing returns.
Cognitive and physiological decline: High doses of morphine or fentanyl cause sedation, constipation, and respiratory depression, stripping patients of their autonomy and ability to interact with loved ones in their final months.
Immunosuppression: Emerging data suggests that chronic opioid use may suppress Natural Killer (NK) cell activity, potentially compromising the body's anti-tumor immune surveillance.

The limitations of these standard-of-care agents create a clear imperative for innovation. We require therapeutic agents that act rapidly, possess a high safety margin, address the specific neurobiology of cancer-induced inflammation, and provide relief from neuropathic pain without heavy sedation. Ketamine emerges as the leading candidate to fill this void.

3. Ketamine Basic Science: Mechanisms of Action

Ketamine is often misunderstood as merely a "horse tranquilizer" or a "club drug." In reality, it is a sophisticated modulator of the central nervous system with a unique mechanism of action that targets the very pathways disrupted by chronic stress, pain, and systemic inflammation.

3.1 The Glutamate Hypothesis and Synaptic Plasticity

Unlike traditional antidepressants that target monoamines (serotonin, dopamine, norepinephrine), ketamine acts on Glutamate, the brain's primary excitatory neurotransmitter.

NMDA Receptor Antagonism:

The core mechanism of ketamine is the non-competitive antagonism of the N-methyl-D-aspartate (NMDA) receptor. In states of chronic depression and chronic pain, the glutamatergic system becomes dysregulated. Excessive glutamate signaling leads to "excitotoxicity," resulting in the atrophy of dendritic spines and the loss of synaptic connections in key brain regions like the prefrontal cortex (responsible for executive function and mood regulation) and the hippocampus (responsible for memory and emotion).

When ketamine blocks the NMDA receptor on GABAergic interneurons (the "brakes" of the brain), it leads to a paradoxical disinhibition of glutamate release. This surge of glutamate then activates a different receptor, the AMPA receptor.

The AMPA-BDNF Cascade:

The activation of AMPA receptors triggers a rapid intracellular signaling cascade involving the mTOR pathway (mammalian target of rapamycin). This pathway upregulates the synthesis and release of Brain-Derived Neurotrophic Factor (BDNF).

Neuroplasticity: BDNF acts as a growth factor for neurons, promoting "synaptogenesis" — the rapid regrowth of synaptic connections.
The "Reboot" Effect: This restoration of neural connectivity essentially "reboots" the depressed brain, restoring the structural integrity of mood-regulating circuits. Remarkably, this structural regrowth can be observed within 24 hours of a single infusion, explaining the rapid onset of clinical relief.

3.2 The Anti-Inflammatory Hypothesis: Bridging Cancer and Mood

Perhaps the most compelling scientific rationale for using ketamine in oncology is its potent anti-inflammatory profile. It is now widely accepted that depression in the medically ill is an inflammatory disorder.

The Cytokine Trap:

Malignant tumors secrete pro-inflammatory cytokines, particularly Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α).

These cytokines cross the blood-brain barrier and activate microglia, the brain's resident immune cells.
Activated microglia release inflammatory mediators that hijack the metabolism of Tryptophan (the precursor to serotonin).
Instead of becoming serotonin, tryptophan is shunted down the Kynurenine Pathway, producing neurotoxic metabolites like Quinolinic Acid.
Quinolinic acid is a potent NMDA receptor agonist, causing further excitotoxicity and driving symptoms of "sickness behavior" — anhedonia, fatigue, and psychomotor retardation.

Ketamine's Intervention:

Ketamine directly disrupts this inflammatory cascade at multiple points:

Reduction of Cytokines: Clinical and preclinical studies consistently show that ketamine administration reduces serum levels of IL-6, IL-1β, and TNF-α. This reduction is often correlated with the improvement in depressive symptoms, particularly anhedonia (the inability to feel pleasure).
Inhibition of the Kynurenine Pathway: By reducing inflammation, ketamine helps restore normal tryptophan metabolism, reducing the production of neurotoxic quinolinic acid and allowing serotonin synthesis to resume.
Microglial Suppression: Recent research into the (R)-enantiomer of ketamine suggests it has a specific ability to suppress microglial activation, thereby halting neuroinflammation at its source.

Conclusion on Mechanism:

For the cancer patient, depression is often a biological consequence of the tumor's inflammatory signal. Treating this with an SSRI is akin to trying to fill a bucket with a hole in it. Ketamine patches the hole by suppressing the inflammation and repairing the neural circuitry, making it a biologically superior intervention for cancer-associated depression.

4. Ketamine for Mental Health in Oncology: Clinical Evidence

The transition of ketamine from the operating room to the psychiatric clinic has been driven by robust data demonstrating its efficacy in "treatment-resistant" populations. In recent years, specific attention has turned to its application in the oncology setting, where it addresses both acute biological depression and profound existential distress.

4.1 Rapid Treatment of Depression and Suicidality

The most critical attribute of ketamine in the palliative context is speed. A systematic review of randomized clinical trials (RCTs) specifically involving cancer patients confirmed that sub-anesthetic ketamine is a "tolerable and effective drug to control depression symptoms".

Key Findings from Clinical Trials:

Rapid Onset: Unlike the 4-6 week lag of SSRIs, ketamine demonstrates antidepressant effects within 40 minutes to 4 hours post-infusion. For a patient with a limited life expectancy, this immediacy is invaluable.
Anti-Suicidal Action: Ketamine possesses a specific anti-suicidal effect that is independent of its antidepressant effect. It can extinguish suicidal ideation (SI) often after a single treatment. In a population where the suicide risk is significantly elevated — particularly in the first year after diagnosis — this rapid stabilization can be lifesaving.
Perioperative Prevention: Studies utilizing ketamine during cancer surgery (e.g., mastectomy or tumor resection) have shown that a single intraoperative dose can significantly reduce the incidence of post-operative depression weeks later. One study demonstrated that HADS-D (depression) scores were significantly lower at days 14, 21, and 28 in the ketamine group compared to placebo.

Table 1: Comparative Onset of Action in Antidepressant Therapies

Feature	SSRIs (e.g., Prozac, Lexapro)	Ketamine Therapy
Mechanism	Monoamine Reuptake Inhibition	NMDA Antagonism / Glutamate Modulation
Time to Onset	4 – 6 Weeks	1 – 24 Hours
Response Rate	~30-40% in Treatment Resistant Depression	~70% in Treatment Resistant Depression
Effect on Suicidality	May initially increase risk (Black Box Warning)	Rapidly reduces ideation
Anti-Inflammatory	Minimal / Indirect	Potent / Direct

4.2 Addressing Existential Distress: The Role of Dissociation

Beyond biological depression, cancer patients suffer from "Existential Distress" — a confrontation with mortality that generates profound fear, regret, and loss of meaning. Standard psychiatry often fails here because the distress is not a pathology of mood, but a crisis of the self.

The "Psychedelic" Advantage:

Ketamine is a "dissociative" anesthetic. In the context of Ketamine-Assisted Psychotherapy (KAP), this dissociative quality is utilized therapeutically. At sub-anesthetic doses, ketamine induces a non-ordinary state of consciousness often described as an "ego-dissolving" experience.

The Overview Effect: Patients report a sensation of stepping outside their immediate narrative of suffering. This "time out" from the rigid grip of fear allows them to view their life, their relationships, and their diagnosis with a sense of objective distance and equanimity.
Disrupting Rigid Patterns: Chronic anxiety creates rigid neural pathways (ruts) of catastrophic thinking. Ketamine's induction of neuroplasticity temporarily "loosens" these rigid patterns, creating a window of flexibility where a therapist can introduce new perspectives that the patient is finally able to internalize.

Clinical Evidence in Palliative Care:

Research at major centers like the Huntsman Cancer Institute has pioneered the use of KAP for terminally ill patients. The "Conscious Dying/Conscious Living" protocols involve preparatory psychotherapy, followed by ketamine dosing sessions, and subsequent integration therapy.

Results: Pilot data suggests that this combination leads to significant improvements in "Death Anxiety" and "Demoralization" scales, with patients reporting a renewed sense of connection and peace that persists long after the drug has left their system.
The Therapeutic Container: It is crucial to note that these benefits are maximized when ketamine is paired with psychotherapy. The drug opens the door; the therapy helps the patient walk through it. This underscores the importance of the integrative model practiced at West Eastern Health, where medication is not dispensed in a vacuum but embedded in a supportive clinical relationship.

4.3 Case Concept: The Patient Journey

Consider a hypothetical patient, "Sarah," a 45-year-old mother diagnosed with Stage IV breast cancer. She presents with severe anxiety, insomnia, and a sense of profound hopelessness ("What's the point?"). She has tried two different SSRIs with no benefit and intolerable nausea.

Intervention: Sarah undergoes a protocol of 6 ketamine infusions over 3 weeks at West Eastern Health, accompanied by integration therapy.
Response: By the second infusion, she reports a "lifting of the fog." Her constant ruminative thoughts about death quiet down. She is able to sleep. By the end of the course, she has not been "cured" of cancer, but she has been cured of the paralysis of fear. She begins to engage with her family again, planning for the future with acceptance rather than terror. This restoration of "functional living" in the face of dying is the hallmark success of ketamine therapy in oncology.

5. Ketamine for Cancer Pain: A Non-Opioid Alternative

While the mental health applications are profound, ketamine's role as an analgesic is equally vital. The management of cancer pain — particularly neuropathic pain — remains a significant challenge, with opioids often failing to provide relief despite dangerous dose escalations.

5.1 Mechanism in Pain: Reversing Central Sensitization

Cancer pain is rarely simple. It is often a mix of nociceptive (tissue damage) and neuropathic (nerve damage) pain. Neuropathic pain acts differently; it is characterized by "Central Sensitization" or the "Wind-Up" phenomenon in the spinal cord.

The Wind-Up: Repetitive firing of pain signals causes the NMDA receptors in the dorsal horn of the spinal cord to become hypersensitive. They amplify incoming signals, such that even a light touch can be perceived as agonizing pain (allodynia).
Opioid Failure: Opioids act on Mu receptors, not NMDA receptors. Therefore, they are often ineffective at stopping this "wind-up," leading physicians to prescribe higher and higher doses in a futile attempt to control the pain.
Ketamine's Role: As an NMDA antagonist, ketamine blocks this specific receptor, effectively "resetting" the pain threshold and stopping the central sensitization. This makes it uniquely effective for the burning, shooting pain of neuropathy that opioids miss.

5.2 The Opioid-Sparing Effect

The concept of "opioid sparing" is critical in modern oncology. Reducing the total opioid load improves the patient's quality of life by reducing sedation, confusion, and constipation.

Clinical Data: A study published in the Kosin Medical Journal involving 253 stage IV cancer patients found that the addition of intravenous ketamine was associated with a nearly 4-fold increase (Odds Ratio 3.84) in the likelihood of favorable pain control compared to standard care.
Reduction in Morphine Equivalents: In complex palliative care cases, ketamine "burst" protocols (continuous infusions over several days) have been shown to reduce the daily morphine requirement by up to 73% while simultaneously improving pain scores.
Chemotherapy-Induced Peripheral Neuropathy (CIPN): Agents like Paclitaxel, Docetaxel, and Vincristine cause painful neuropathy in nearly 70% of patients. This pain is notoriously difficult to treat. Ketamine topical gels and systemic infusions are emerging as one of the few interventions that can mitigate this specific type of nerve damage pain.

5.3 Administration Protocols for Pain

Unlike the short, 40-minute infusions used for depression, pain protocols often require longer durations or higher doses to achieve receptor saturation in the spinal cord.

Infusion Duration: Pain infusions may last 2 to 4 hours.
Routes: While IV is the gold standard, oral, intranasal, and subcutaneous routes are also utilized for maintenance therapy in the outpatient or hospice setting. The flexibility of administration allows West Eastern Health to tailor the approach to the patient's comfort and mobility needs.

Table 2: Efficacy of Ketamine in Refractory Cancer Pain Scenarios

Pain Type	Mechanism	Ketamine Efficacy	Evidence Support
Nociceptive (Bone mets, visceral)	Tissue damage / inflammation	Moderate (Adjunct)	Effective primarily via anti-inflammatory action
Neuropathic (Tumor invasion)	Nerve damage / signaling error	High	Primary indication; blocks NMDA wind-up
CIPN (Chemo-induced)	Axonal degeneration	High	Addresses mechanistic nerve hyperexcitability
Opioid-Induced Hyperalgesia	Central sensitization	High	Only known agent to effectively reverse OIH

6. Safety, Risks, and Controversies: A Balanced Review

While ketamine is a powerful tool, it is not without risks. Its use in the medically complex oncology population requires rigorous oversight and a nuanced understanding of its physiological effects. A balanced view of the pros and cons is essential for informed consent.

6.1 Hemodynamic and Respiratory Stability (The Pros)

One of ketamine's greatest assets is its safety profile regarding vital signs.

Respiratory Drive: Unlike opioids and most sedatives (e.g., propofol), ketamine does not suppress the respiratory drive. The patient continues to breathe spontaneously. This is a crucial safety margin for cancer patients who may have lung metastases, pleural effusions, or are on high-dose opioids that already compromise breathing.
Cardiovascular Support: Ketamine is a sympathomimetic, meaning it typically causes a mild, transient increase in heart rate and blood pressure. For patients who are cachectic, dehydrated, or hypotensive — common states in advanced cancer — this "hemodynamic support" is preferable to agents that cause hypotension.

6.2 Managing Dissociative Side Effects (The Cons)

The same "dissociation" that is therapeutic for some can be distressing for others.

Psychomimetic Effects: During the infusion, patients may experience visual hallucinations, a sense of floating, or time distortion.
Mitigation: These effects are dose-dependent and transient, ending rapidly when the infusion stops. At West Eastern Health, these are managed through "Set and Setting" — a calm environment, preparatory counseling, and the presence of a skilled clinician. If the dissociation becomes dysphoric (unpleasant), it can be rapidly terminated with small doses of benzodiazepines (e.g., midazolam), though this is rarely necessary with proper preparation.

6.3 Addressing the "Myths" and Real Risks

The Intracranial Pressure (ICP) Myth

A longstanding dogma in medicine held that ketamine increases Intracranial Pressure (ICP), making it dangerous for patients with brain tumors or metastases.

The Reality: Modern research has thoroughly debunked this. Systematic reviews of neurocritical care data show that ketamine does not dangerously elevate ICP when patients are properly ventilated. In fact, by maintaining blood pressure, it ensures the brain receives adequate oxygen (Cerebral Perfusion Pressure). It is now often the sedative of choice for head trauma.
Conclusion: The presence of brain metastases is not an absolute contraindication, though such cases should always be managed in consultation with the patient's oncologist.

Cystitis and Bladder Toxicity

Chronic, high-dose recreational abuse of ketamine (e.g., grams per day for years) is associated with severe ulcerative cystitis (bladder damage).

Clinical Context: The doses used for depression and pain are a fraction of recreational doses and are administered intermittently. Consequently, ketamine-induced cystitis is extremely rare in the clinical setting. However, vigilance is maintained. Patients with active bladder cancer or radiation cystitis require careful risk-benefit analysis and monitoring for urinary symptoms.

Interaction with Chemotherapy: The CYP3A4 Pathway

Ketamine is metabolized in the liver primarily by the cytochrome P450 enzyme CYP3A4 (and to a lesser extent CYP2B6).

The Conflict: Many chemotherapy agents, particularly Taxanes (Paclitaxel, Docetaxel) and Vinca Alkaloids (Vincristine), are also substrates of CYP3A4.
The Risk: If given simultaneously, they could compete for the enzyme, potentially altering the blood levels of the chemotherapy (leading to toxicity) or the ketamine (leading to prolonged sedation).
The Solution: This is a manageable pharmacokinetic interaction. It relies on timing. Standard guidance suggests separating the administration of ketamine and taxanes by at least 24 hours to allow for clearance. This highlights the importance of the integrated care model at West Eastern Health, where our providers coordinate directly with the oncology team.

The Tumor Growth Debate

Does ketamine affect cancer cells directly?

Pro-Tumor Concerns: Some older preclinical data suggested ketamine might suppress Natural Killer (NK) cell activity or upregulate metastasis-related genes (e.g., WNT5A, EGFR).
Anti-Tumor Evidence: More recent and robust studies contradict this. Ketamine has been shown to induce ferroptosis (iron-dependent cell death) in breast cancer cells, inhibit the PI3K/Akt/mTOR pathway (a common driver of tumor growth), and reduce tumor retention in lungs compared to other anesthetics.
Consensus: The data is complex and likely cancer-type specific. However, there is no clinical evidence in humans that therapeutic ketamine worsens cancer prognosis. Conversely, untreated depression and chronic stress are known to create a pro-tumor environment via cortisol and inflammation. Therefore, alleviating distress with ketamine likely has a net positive biological impact.

7. The West Eastern Health Integrative Model

The data presented above confirms that ketamine is a powerful pharmacological agent. However, at West Eastern Health, we believe that a drug is only as effective as the system in which it is delivered. We do not view ketamine as a standalone "magic bullet," but as a catalytic "pillar" within our broader framework of Integrative Mental Health.

7.1 Synergy with the "Six Pillars of Wellness"

Our clinic employs a comprehensive approach where ketamine therapy enhances the efficacy of other treatment modalities:

Nutritional Guidance: Ketamine acts as an anti-inflammatory, but a poor diet can fuel inflammation. We pair infusions with functional nutrition plans that support the brain's repair process, providing the metabolic building blocks (omega-3s, antioxidants) needed for BDNF synthesis and neuroplasticity.
Mindfulness and Breathwork: The "neuroplastic window" opened by ketamine lasts for several days post-infusion. This is a critical period for "rewiring" the brain. Engaging in mindfulness and breathwork during this window helps solidify new, positive neural pathways, converting a temporary state of relief into a permanent trait of resilience.
Psychedelic-Assisted Psychotherapy: As detailed in the section on existential distress, the "integration" sessions provided by our specialized therapists are where the true healing occurs. We help patients process the insights gained during the infusion, translating the abstract experience of "letting go" into actionable emotional shifts in their daily lives.

7.2 Personalized, Patient-Centered Protocols

We reject the "assembly line" model of ketamine clinics. Recognizing the fragility and complexity of the cancer patient, our protocols are highly individualized:

Collaborative Care: We work in concert with the patient's primary oncologist to ensure safety regarding chemotherapy schedules and blood counts.
Tailored Dosing: We adjust dosages based on the patient's specific needs — using lower, psycholytic doses for existential exploration and higher, analgesic doses for neuropathic pain control.
Environment: Our clinic offers a "safe and supportive environment" designed to minimize anxiety and maximize the therapeutic potential of the experience.

8. Conclusion: A New Horizon in Cancer Care

The journey of cancer is often described as a battle, but for many patients, the hardest battles are not fought against the tumor, but against the despair, the pain, and the loss of self that accompanies the disease.

The science is clear: the mental health and pain mechanisms in cancer are biologically distinct, driven by inflammation and neuro-excitotoxicity that standard antidepressants and opioids often fail to address. Ketamine represents a breakthrough because it targets these specific mechanisms. It offers the possibility of rapid relief from depression, the reversal of opioid-resistant pain, and a pharmacological key to unlock the existential rigidity that traps patients in fear.

However, its power demands responsibility. It requires a clinical team that understands the nuances of CYP3A4 interactions, the delicate balance of palliative sedation, and the profound psychological depth of the dissociative experience.

At West Eastern Health, we are dedicated to providing this expert, integrative care. We invite patients, families, and oncology providers to explore how this innovative therapy can be woven into the fabric of cancer treatment — not as a replacement for oncology, but as a vital partner in restoring the quality of life that makes survival meaningful.

9. Technical Appendix: Data Tables and Reference Synthesis

Table 3: Summary of Key Clinical Trials in Cancer Populations

Study / Source	Population	Intervention	Outcome	Significance
Systematic Review 2023	5 RCTs (Inpatient Cancer)	IV Ketamine (Sub-anesthetic)	Significant reduction in depression scores	Establishes efficacy in active cancer treatment settings
Kosin Med J 2021	253 Stage IV Patients	IV Ketamine + Standard Care	OR 3.84 for favorable pain control	Strong evidence for opioid-sparing effect in advanced disease
Falk et al.	Surgical Oncology Patients	Single Perioperative Dose	Reduced HADS-D scores at Day 28	Suggests prophylactic potential against post-diagnosis depression
Huntsman Cancer Inst.	Terminal Diagnosis	Ketamine-Assisted Psychotherapy	Improvement in existential distress	Validates the "Psychotherapy + Medicine" model for demoralization

Table 4: Drug Interaction Reference for Oncologists

Chemotherapy Class	Specific Agents	Interaction Mechanism	Recommendation
Taxanes	Paclitaxel, Docetaxel	CYP3A4 Substrate Competition	Space by 24 hours. Monitor for increased sedation or chemo toxicity
Vinca Alkaloids	Vincristine, Vinblastine	CYP3A4 Substrate	Space treatments. Monitor for neurotoxicity (ketamine may help alleviate induced neuropathy)
Anthracyclines	Doxorubicin	Minimal CYP interaction	Generally safe to co-administer, though cardiac monitoring (standard for Dox) covers ketamine's mild pressor effect
Platinum Agents	Cisplatin, Carboplatin	Renal clearance / Ototoxicity	Safe. Ketamine is not nephrotoxic and does not compound renal risks

Disclaimer: This white paper is intended for educational purposes for patients and healthcare providers. It does not constitute specific medical advice. All medical treatments involve risk and should be undertaken under the supervision of a qualified physician.

References

Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline. PMC.
Depression and anxiety among people living with and beyond cancer: a growing clinical and research priority. PMC.
Ketamine Use for Cancer and Chronic Pain Management. PubMed.
Ketamine Use for Cancer and Chronic Pain Management. PMC.
Lauren Marchefka Press Release. West Eastern Health.
July 2024 WEH Monthly Newsletter. West Eastern Health.
Prevalence of depression and anxiety among newly diagnosed cancer patients. ecancer.
Psilocybin-assisted psychotherapy for existential distress. Annals of Palliative Medicine.
Efficacy comparison of five antidepressants in treating anxiety and depression in cancer and non-cancer patients. Frontiers in Neuroscience.
Inflammation, stress and depression: an exploration of ketamine's therapeutic profile. PMC.
Ketamine Prevents Inflammation-Induced Reduction of Human Hippocampal Neurogenesis. Oxford Academic.
Ketamine burst protocol: achieving pain control and opioid sparing in refractory neuropathic pain. BMJ Supportive & Palliative Care.
Perioperative Ketamine and Cancer Recurrence: A Comprehensive Review. PMC.
Ketamine's Role in Neuroinflammation and Neuroprotection. PMC.
Ask an Expert: Ketamine for Patients with Cancer. University of Utah Health.
Antidepressant mechanisms of ketamine: a review of actions with relevance to treatment-resistance. Frontiers in Neuroscience.
Ketamine's effect on inflammation and kynurenine pathway in depression. PMC.
Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine. MDPI.
The efficacy and safety of ketamine for depression in patients with cancer: A systematic review. PubMed.
The efficacy and safety of ketamine for depression in patients with cancer. PMC.
Advances in the Therapeutic Effects of Ketamine on Cancer Pain Related Depression. Translational Perioperative and Pain Medicine.
Ketamine and Ketamine-Assisted Psychotherapy for Psychiatric and Existential Distress. PubMed.
Use of ketamine for depression and suicidality in cancer and terminal patients. PMC.
Efficacy and safety of ketamine for the treatment of depressive symptoms in palliative care. PMC.
Facing a terminal diagnosis with the help of ketamine. University of Utah.
Ketamine-assisted Psychotherapy for Improving Existential Distress in Patients with Non-operable Gastrointestinal Cancers. NCI.
Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy. ClinicalTrials.gov.
Ketamine-Assisted Psychotherapy for Patients with Cancer. ScholarWorks @ SeattleU.
The effects of ketamine on pain control in stage IV cancer patients. Kosin Medical Journal.
Review of the Interactions Between Anesthetic Agents and Chemotherapeutic Agents. PMC.
How Long Does Ketamine Treatment Last? Illinois Pain & Spine Institute.
Effects of intranasal ketamine on uncontrolled cancer related pain. PMC.
Ketamine Protocol for Palliative Care in Cancer Patients With Refractory Pain. PMC.
Should Ketamine Be Contraindicated for Patients with Traumatic Brain Injury? JEMS.
The emerging use of ketamine for anesthesia and sedation in traumatic brain injuries. PubMed.
Effects of Low Doses of Ketamine on Intracranial Pressure. JPTCP.
The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. PMC.
Recreational ketamine use can lead to irreversible bladder damage. NZMJ.
Ketamine cystitis following ketamine therapy for treatment-resistant depression. PMC.
Ketamine-Induced Cystitis: A Comprehensive Review. PMC.
Ketamine metabolism via hepatic CYP450 isoforms. bioRxiv.
Drug interactions with the taxanes. PubMed.
Paclitaxel Drug-Drug Interactions in the Military Health System. MDedge.
Drug interactions with the taxanes: clinical implications. PubMed.
Ketamine Promoted Breast Cancer Invasion and Metastasis. Anticancer Research.
Ketamine inhibits endometrial cancer cell growth by inducing ferroptosis. EJGO.
Alleviating role of ketamine in breast cancer cell-induced osteoclastogenesis. PMC.
Systemic Anticancer Therapy Drug Interactions Table. Northern Cancer Alliance.